Kiora Pharmaceuticals Inc. (NASDAQ: KPRX)
$4.35
+0.0600 ( +1.40% ) 24.1K
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Market Data
Open
$4.35
Previous close
$4.29
Volume
24.1K
Market cap
$12.76M
Day range
$4.22 - $4.36
52 week range
$3.60 - $8.98
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jul 03, 2024 |
4 | Insider transactions | 1 | Jul 03, 2024 |
4 | Insider transactions | 1 | Jul 03, 2024 |
4 | Insider transactions | 1 | Jul 03, 2024 |
4 | Insider transactions | 1 | Jul 03, 2024 |
4 | Insider transactions | 1 | Jul 03, 2024 |
4 | Insider transactions | 1 | Jul 03, 2024 |
3 | Insider transactions | 5 | Jul 03, 2024 |
4 | Insider transactions | 1 | Jul 03, 2024 |
4 | Insider transactions | 1 | Jul 03, 2024 |